WASHINGTON (December 19) –   Today, the Center for Medicare and Medicaid Innovation (CMMI) announced a proposed series of Medicare drug pricing demonstrations affecting some Part B  and Part D  medicines, respectively. The Global Benchmark for Efficient Drug Pricing (GLOBE) and Guarding U.S. Medicare Against Rising Drug Costs (GUARD) demonstrations would significantly restructure Medicare drug reimbursement and coverage, pegging Medicare Part B and Part D drug prices to those

WASHINGTON ( December 2 ) -- Yesterday, the United States and the United Kingdom announced  a new agreement on pharmaceutical pricing as part of the Economic Prosperity Deal (EPD). The agreement is expected to increase the U.K.'s valuation of new medicines and expand its long-term investment in innovative therapies. The United States, in turn, committed to exempt U.K.-origin pharmaceuticals from any future Section 232 tariffs and to refrain from targeting U.K. pricing polici

WASHINGTON ( November 26) -- Yesterday, the Trump administration announced Maximum Fair Prices (MFPs) for the next 15 Medicare Part D drugs selected for price setting under the Medicare Drug Price Negotiation Program. The new prices take effect in January 2027.   Incubate's executive director, John Stanford, issued the following statement in response to the announcement:   " Today's announcement is another reminder of the fundamental flaws in existing federal drug-pricing p

WASHINGTON ( Sep 30 ) -- Today, the Trump administration announced its first agreement with a manufacturer to bring most-favored-nation...

WASHINGTON, D.C. ( September 26 ) -- Yesterday, President Trump announced  sweeping tariffs of 100% on brand-name and patented...